课题基金 / 基金详情

Genomics and post-genomics of Staphylococcus aureus causing bullous impetigo

Genomics and post-genomics of Staphylococcus aureus causing bullous impetigo
引起大疱性脓疱病的金黄色葡萄球菌的基因组学和后基因组学
批准号:
15390143
负责人:
SUGAI Motoyuki
金额:
$8.51万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

SUGAI Motoyuki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In this study, we collected bacterial specimens by seed swab from lesions of bullous impetigo patients with the cooperation of more than 60 nation-wide hospitals and open clinics in Japan and isolated Staphylococcus aureus in our laboratory. We identified 1,017 S.aureus strains. The isolated strains were subjected to PFGE by SmaI digestion, Southern hybridization for genes of eta,etb,etd, coagulase testing, agglutination test for SEA,SEB,SEC,SED,PCR testing for eta,etb, etd,sea, seb,sec,sed,tsst-1,femA,mecA. The overaII PFGE patterns of isolated strains weresubjected to clustering analysis by Gel Compar. Isolated strains were also subjected for measurement of MIC against cefem, macrolide, fusigic acid, tetracycline, quinolone. Upon these characterization, we discovered that strains causing bullous impetigo in Japan were clustered in five clonal groups and their producibility of exfoliative toxin, coagulase types well correlated with clustering results, i.e.there are three ETA-producing clusters, one ETB-producing and one ETD-producing clusters. Three ETA-producing clusters are coagulase type V,III, and VII respectively. ETB-producing cluster is type I and ETD-producing cluster is type II. Surprisingly, 100% of coagulase type III ETA-producing cluster is mecA positive and 70% of ETB-producing cluster is mecA positive. Multilocus sequencing results well correlated with clustering analysis indicating their clonality. MIC testing clearly indicated that those mecA positive strains are borderline level resistant to β-lactams. These results strongly suggested that in Japan now teo clonal groups causing bullous impetigo are expanding as MRSA.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/j.1365-2958.2004.04200.x
发表时间: 2004-08-01
期刊: MOLECULAR MICROBIOLOGY
影响因子: 3.6
作者: [Komatsuzawa, H, Fujiwara, T, Sugai, M]
通讯作者: Sugai, M
Bullous impetigo and Staphylococcus aureus
大疱性脓疱病和金黄色葡萄球菌
DOI: --
发表时间: 2005
期刊: Antibiotics and chemotherapy vo1.21 No.3
影响因子: --
作者: [Motoyuki Sugai, Takayuki Yamaguchi]
通讯作者: Takayuki Yamaguchi
MRSA is increasing in S.aureus causing bullous impetigo.
MRSA 在金黄色葡萄球菌中增加,导致大疱性脓疱病。
DOI: --
发表时间: 2003
期刊: Current Topics No.55
影响因子: --
作者: [Someya K et al., Motoyuki Sugai]
通讯作者: Motoyuki Sugai
DOI: 10.1128/jb.187.2.480-487.2005
发表时间: 2005-01-01
期刊: JOURNAL OF BACTERIOLOGY
影响因子: 3.2
作者: [Fujiwara, T, Aoki, S, Sugai, M]
通讯作者: Sugai, M
15
    Intranuclear action of Cell cycle-specific growth inhibitory factor, CDT
    • 批准号:
      20592140
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2008
    • 负责人:
      SUGAI Motoyuki
    • 依托单位:
    Integrated Research on pathogenic factors of periodontal pathogens
    • 批准号:
      17591912
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2005
    • 负责人:
      SUGAI Motoyuki
    • 依托单位:
    Genome-wide study on pathogenesis of bacteria causing nosocomial infection
    • 批准号:
      17019048
    • 项目类别:
      Grant-in-Aid for Scientific Research on Priority Areas
    • 资助金额:
      $62.4万
    • 财政年份:
      2005
    • 负责人:
      SUGAI Motoyuki
    • 依托单位:
    A study on the function of cell-cycle specific inhibitor, CDT
    • 批准号:
      12470064
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.15万
    • 财政年份:
      2000
    • 负责人:
      SUGAI Motoyuki
    • 依托单位:
    国内基金
    海外基金
    去铁胺修饰Fe3+-鞣花酸纳米酶敷料靶向杀灭MRSA促进糖尿病伤口愈合机制
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      谢颖
    • 依托单位:
    野菊花内生真菌中抗MRSA活性成分及其作用机制
    • 批准号:
      JCZRLH202601040
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    小分子化合物T-2307及其类似物通过PG-PMF-ATP通路抗MRSA感染的分子机制及应用研究
    靶向新航向:STAT3抑制剂对MRSA的抗菌作用及其分子机制研究
    • 批准号:
      2026JJ50552
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      吴苑
    • 依托单位: